Navigation Links
Advances in delivery of therapeutic genes to treat brain tumors
Date:6/27/2011

New Rochelle, NY, June 27, 2011Novel tools and methods for delivering therapeutic genes to cells in the central nervous system hold great promise for the development of new treatments to combat incurable neurologic diseases. Five of the most exciting developments in this rapidly advancing field are presented in a series of articles in the June issue of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The articles are available free online at www.liebertpub.com/hum

A review article by Betley and Sternson, "Adeno-Associated Viral Vectors for Mapping, Monitoring, and Manipulating Neural Circuits," highlights the latest genetic tools that are enabling cell type-specific delivery of transgenes for studying the structure and function of neuronal circuits.

Ryu et al. report on the successful use of stem cells derived from human umbilical cord blood to deliver a novel therapeutic geneinterleukin-12to the brain for long-term anti-tumor activity against gliomas, a deadly type of brain tumor. Their innovative strategy is presented in the research report "Gene Therapy of Intracranial Glioma Using Interleukin 12-Secreting Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells."

"High-Density Lipoprotein Facilitates In Vivo Delivery of α-Tocopherol-Conjugated Short-Interfering RNA to the Brain" by Uno et al. describes a combination strategy for dramatically improved delivery of siRNAs to the brain to silence genes involved in neurological disease.

Loss of the neurotrophic factor GDNF contributes to the development of neuropathic pain caused by trauma or neurodegenerative disease. Shi et al. present data to support this link and demonstrate the potential to replace GDNF via intramuscular gene delivery in the article "Glial Cell Line-Derived Neurotrophic Factor Gene Transfer Exerts Protective Effect on Axons in Sciatic Nerve Following Constriction-Induced Peripheral Nerve Injury."

The use of adenoviral vectors as carriers of therapeutic genes to the cerebrospinal fluid has the potential to enable long-term gene expression for the treatment of neurological diseases. In the brief report "Intrathecal Injection of Helper-Dependent Adenoviral Vectors Results in Long-Term Transgene Expression in Neuroependymal Cells and Neurons" Dindot et al. describe the successful use of adenoviral vectors to transduce neuronal cells.

"Treating neurologic diseases with traditional biologic products such as therapeutic proteins has been challenging due to limited access. The use of vectors helps to overcome these barriers," says James M. Wilson, MD, PhD, Editor-in-Chief, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Related medicine news :

1. New advances in lipid genetics lead to better detection and prevention of major diseases
2. Led by advances in chemical synthesis, scientists find natural product shows pain-killing properties
3. Society of Interventional Radiology addresses radiation safety, advances best practices
4. Experts to discuss advances in dental sleep medicine treatments for sleep-disordered breathing
5. UT Southwestern research advances fight against kidney cancer
6. Research presented at 2011 GU Cancers Symposium highlights advances in treatment of prostate cancer
7. RIC study suggests researchers are entering a new era of advances in brain research
8. Long-shot discovery may lead to advances in treating anxiety, memory disorders
9. Roundup: 2010 Advances in Heart Disease and Stroke Care
10. Ovarian cancer advances when genes are silenced
11. Blood Cancer Advances May Improve Survival
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Advances in delivery of therapeutic genes to treat brain tumors 
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
Breaking Medicine Technology: